Understanding the benefit of metformin use in cancer treatment.
Dowling RJ, Goodwin PJ, Stambolic V. · 2011
Read Understanding the benefit of metformin use in cancer treatment. by Dowling RJ, Goodwin PJ, Stambolic V. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3224599.txt.
Description
Ryan Dowling, Pamela Goodwin, and Vuk Stambolic reviewed the case for the diabetes drug metformin as a cancer treatment in this 2011 article in BMC Medicine. Metformin is the most widely prescribed drug of its class for type 2 diabetes. Population, laboratory, and early clinical evidence had begun to suggest it might also fight cancer.
The authors set out two routes by which the drug could help. By lowering circulating insulin, it may starve cancers that thrive on high insulin, such as breast and colon tumors. It may also act directly on cancer cells by blocking the mTOR signaling pathway, which controls protein production and growth. The review weighs the supporting evidence and the molecular mechanisms, framing metformin as a promising repurposed therapy.
Catalog record
| CREATOR | Dowling RJ, Goodwin PJ, Stambolic V. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |